Digital microfluidics as the optimal technology for bacterial protocol advances

The February 2023 issue of SLAS Technology contains a set of four original research articles and one review article covering digital microfluidics (DMF), cryopreservation, colorectal cancer research and other laboratory automation technology.

This month's featured article, "Digital microfluidics as an emerging tool for bacterial protocols," by Nemr, et al, provides a full assessment of DMF – an advanced liquid handling technology that utilizes electrostatic forces to manipulate microdroplets on a plate. The authors' assessment of DMF was based on 15 years' worth of compiled research and development on the technique.

DMF is used in synthetic biology (ligation, transformation and induction), diagnostics (nucleic acid detection and antibiotic susceptibility testing), and bacterial protocols for sample preparation. However, the authors identify additional applications that DMF may serve as the optimal technology for bacterial protocol advances due to its versatility.

Source:
Journal reference:

Nemr, C.R., et al. (2022) Digital microfluidics as an emerging tool for bacterial protocols. SLAS Technology. doi.org/10.1016/j.slast.2022.10.001.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New Method for Identifying Kinase Inhibitors for Cancer Therapy